ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Transfemoral Transcatheter Aortic Valve Implantation (TF-TAVI) for Patients With Left Ventricular Assist Device (LVAD) and Aortic Regurgitation.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transfemoral Transcatheter Aortic Valve Implantation (TF-TAVI) for Patients With Left Ventricular Assist Device (LVAD) and Aortic Regurgitation.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aortic regurgitation (AR) develops in up to 25%-30% of patients with left ventricular assist device (LVAD). Treatment remains challenging since surgery confers significant peri-operative risk and the lack of valvular calcification renders transfemoral transcatheter aortic valve implantation (TF-TAVI) with non-dedicated devices technically challenging. We present a case series wherein a TF J-Valve system, a dedicated transcatheter heart valve for pure AR, emerges as an alternative treatment for AR in patients with an LVAD. We demonstrate successful deployment even in the presence of challenging anatomy including aortic root thrombus. Technical considerations when performing TF-TAVI in LVAD patients are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.